Type of Study:

Study Design:

Outcome Measure:

To assess the safety and tolerability of MDV3100 in combination with Docetaxel

Outcome Description:

The primary criteria for the evaluation of safety and tolerability are:
The percentage of patients who require dose reduction of docetaxel and/or MDV3100 following Treatment Periods 1 and 2;
The percentage of patients who discontinue docetaxel or MDV3100 due to an adverse event.

Outcome Time Frame:

30 days

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

MDV3100-06

NCT ID:

NCT01565928

Start Date:

February 2012

Completion Date:

April 2014

Related Keywords:

Prostate Cancer

Prostate cancer

docetaxel

MDV3100

Prostatic Neoplasms

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.